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Abstract
Introduction High-mobility group box chromosomal protein 1
(HMGB1) has recently been identified as an endogenous
mediator of arthritis. TNF and IL-1β, pivotal cytokines in arthritis
pathogenesis, both have the ability to induce the release of
HMGB1 from myeloid and dendritic cells. It was, therefore,
decided to investigate whether treatment based on TNF
blockade in rheumatoid arthritis (RA) affects the expression of
synovial HMGB1.
Methods Repeated arthroscopy-guided sampling of synovial
tissue was performed in nine patients with RA before and nine
weeks after initiation of anti-TNF mAb (infliximab) therapy.
Synovial biopsy specimens were analysed for HMGB1 protein
by immunohistochemical staining and for HMGB1 mRNA
expression by real-time reverse transcriptase PCR (RT-PCR).
Statistical evaluations were based on Wilcoxon's signed rank
tests or Spearman rank sum tests.
Results Aberrant, extranuclear HMGB1 and constitutive
nuclear HMGB1 expression, with histological signs of
inflammation, were evident in all biopsies obtained before
infliximab therapy. Signs of inflammation were still evident in the
second biopsies obtained nine weeks after initiation of infliximab
therapy. The cytoplasmic and extracellular expression of
HMGB1 decreased in five patients, remained unchanged in one
patient and increased in three patients, making the overall
change in HMGB1 protein expression not significant. No
correlation between the clinical response, as measured by
disease activity score calculated for 28 joints (DAS28) or the
American College of Rheumatology response criteria (ACR 20,
50, and 70), and the direction of change of HMGB1 expression
in individual patients could be discerned. In addition, infliximab
therapy did not alter HMGB1 mRNA synthesis.
Conclusion Pro-inflammatory HMGB1 expression during
rheumatoid synovitis was not consistently influenced by TNF-
blocking therapy with infliximab. This suggests that TNF is not
the main inducer of extranuclear HMGB1 during synovitis and
that HMGB1 may represent a TNF-independent molecule that
could be considered as a possible target for future therapeutic
intervention in RA.
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease charac-
terised by chronic polyarticular inflammation leading to the
destruction of cartilage and subchondral bone. The pathogen-
esis of RA is complex, involving a wide range of endogenous
pro-inflammatory molecules including cytokines. Certain medi-
ators, with TNF as one causative molecule, can be success-
fully targeted in the treatment of chronic arthritis. TNF-blocking
therapy has been shown to dramatically reduce inflammation
and tissue destruction in many patients with RA [1-3].Page 1 of 8
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in all patients and that many responders still present residual
signs of active disease. In order to improve the treatment of
chronic arthritis, a further search for additional potential target
molecules that act independently of TNF is highly warranted.
Recent findings have suggested that the high-mobility group
box chromosomal protein 1 (HMGB1) might be an important
molecule in the pathogenesis of arthritis [4-10]. Intranuclear
HMGB1 binds DNA and regulates transcription. In addition,
HMGB1 may be extracellularly translocated, thereby acting as
an inflammatory mediator of tissue invasion and tissue repair
[11-18]. HMGB1 may either be actively secreted from a wide
number of cell types following stimulation with inflammatory
mediators, including TNF, IL-1β, IFN-γ and multiple toll-like
receptor (TLR) ligands [15,19-23], or be passively released
from dying nucleated cells [12,13]. The extracellular effects of
HMGB1 are mediated via multiple receptors including the
receptor for advanced glycated end-products (RAGE), some
members of the TLR family and other as yet unidentified path-
ways [17,24-26]. Increased levels of HMGB1 are evident in
the synovial fluid of patients with RA and HMGB1 has been
shown to be abundantly expressed in an aberrant fashion in
rheumatoid synovial tissue [4,6]. Serum levels of HMGB1 are
also elevated in patients with RA and correlate with disease
activity [27]. In addition, intra-articular injections of HMGB1
trigger destructive arthritis in naive mice [5].
Different modes of HMGB1-blocking therapy, including neu-
tralising antibodies, antagonistic truncated HMGB1, soluable
RAGE (sRAGE), thrombomodulin or nuclear HMGB1 seques-
tration, have been successfully applied in studies of experi-
mental arthritides and sepsis [15,28-33]. It was recently
reported that gold salts interfere with the intracellular transport
mechanisms of HMGB1 and inhibit its release [34]. Oxaliplatin
is an antineoplastic platinum-based compound that generates
DNA adducts that strongly bind HMGB1. Therefore, gold salts
and oxaliplatin share the capacity to inhibit nuclear HMGB1
release via different mechanisms. Short-term oxaliplatin treat-
ment in collagen type-II-induced arthritis was recently studied
in mice and beneficial therapeutic effects coinciding with
nuclear HMGB1 retention were noted [35]. Once released,
HMGB1 might generate a positive feedback loop and induce
production of several pro-inflammatory cytokines such as IL-6,
IL-1β and TNF by macrophages and dendritic cells, thereby
sustaining prolonged inflammation [16,36].
In this pilot study the aim was to analyse to what extent extra-
nuclear HMGB1 expression depends on and relates to TNF
levels in RA, as previous studies have indicated that TNF can
induce HMGB1 release. Synovial biopsy specimens from
patients with RA were collected by arthroscopy before and
during therapy with TNF-specific mAb (infliximab) and the lev-
els of synovial expression of HMGB1 protein and mRNA were
evaluated.
The main findings were that synovial HMGB1 protein and
mRNA expression did not change in any consistent manner
after nine weeks of infliximab treatment.
Materials and methods
Patients, clinical assessment and therapy
Nine patients (seven females and two males) with RA diag-
nosed according to the revised American College of Rheuma-
tology (ACR) criteria [37] and active knee arthritis were
enrolled in a prospective clinical study. Informed consent was
obtained from all patients and the study was approved by the
local ethical committee at Karolinska University Hospital,
Stockholm, Sweden.
The median age of patients was 57 years (range 25 to 69
years) and the median disease duration was six years (range
0.6 to 18 years). The median duration of the current episode
of arthritis in the knee was 17.5 days (range 3 to 365 days; no
data for one patient). In all patients the disease activity score
calculated for 28 joints (DAS28) and the ACR response crite-
ria (ACR20, 50, and 70) were assessed at multiple time points
before and during therapy. The median DAS28 at inclusion
was 5.95 despite treatment with methotrexate (7.5 to 17.5
mg/week). Methotrexate doses were stable during the study
and for at least one month before the first arthroscopy. Four
patients received prednisone at stable doses (5 to 7.5 mg/
day) during the study period. One patient received
cyclosporine (150 mg/day) before and during the study
period.
Infliximab (Centocor BV, Leiden, The Netherlands) was given
as three intravenous infusions of 3 mg/kg in accordance with
the recommended standard-treatment protocol, with the first
infusion given 1 to 21 days after the first arthroscopy and the
subsequent infusions given two and six weeks later. The
results of synovial expression of IL-15 in response to infliximab
therapy using the same cohort of patients with RA have previ-
ously been published [38-40].
Synovial biopsies
Knee arthroscopy with multiple biopsies of synovial tissue of
the knee joint was performed in all patients 1 to 21 days before
the first infliximab infusion. A second arthroscopy was per-
formed at 8 to 10 weeks (median nine weeks) after the first
infusion, a time point when infliximab therapy is well estab-
lished and a clinical response can be evaluated [1].
All arthroscopies were performed by the same experienced
physician (EK). During the first arthroscopy, multiple synovial
tissue biopsies were taken from areas with signs of maximum
macroscopic inflammation, from the cartilage-pannus junction
and from synovial villi. Each biopsy site was documented pho-
tographically and mapped, allowing for follow-up biopsies to
be taken from the same areas. The biopsies were snap-frozen
within two minutes in liquid isopentane and stored at -70°CPage 2 of 8
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20 minutes with 2% (v/v) formaldehyde and stored at -70°C.
Several biopsies were taken to secure sufficient material for
subsequent analyses. For each of the nine patients the best
biopsy pair with respect to morphology was selected for sub-
sequent immunohistochemical stainings. The staining was
always performed for samples taken before and after infliximab
treatment allowing for a pairwise comparison.
Immunohistochemistry
For indirect immunohistochemistry evaluation, tissue sections
were blocked for non-specific binding with H2O2 and NaN3 for
one hour, with normal goat serum (X0907, DAKO, Glostrup,
Denmark) for 15 minutes and with an Avidin/Biotin blocking kit
(SP-2001, Vector Laboratories, Burlingame, CA USA) accord-
ing to the manufacturer's instructions. Saponin (0.1% w/v in
HEPES pH 7.2) was added throughout the staining protocol.
An HMGB1-specific polyclonal peptide-affinity purified rabbit
antibody (PharMingen 556528, San Diego, CA, USA) was
used as the primary antibody at a final concentration of 0.5 μg/
ml. A non-specific rabbit antibody (X0902, DAKO, Glostrup,
Denmark) was used as the control. To identify blood vessels,
a human endothelium-specific mAb (anti-EN4, anti-human
CD31 from Sanbio, Bio-Zac, Uden, The Netherlands) was
used. As the negative control for CD31, an irrelevant mouse
IgG1 mAb (DAKO, Glostrup, Denmark) was also used.
Sections were incubated with primary antibodies overnight.
The secondary antibody was a biotinylated goat anti-rabbit
IgG (BA-1000, Vector Laboratories, Burlingame, CA, USA)
diluted to 1:800 for HMGB1 detection, and a biotin goat anti-
mouse IgG1 (DAKO, Glostrup, Denmark) was used for CD31
detection. Extra-avidin peroxidase (EAP) (Sigma, St. Louis,
MO, USA) with diaminobenzidine (DAB) (Vector Laboratories,
Burlingame, CA, USA) as substrate were used for visualisation
and sections were then counterstained with haematoxylin,
washed, dried and mounted with buffered glycerol.
Two evaluators (ES and CG), blinded to the order of the sec-
tions, performed a semi-quantitative analysis of the expression
of HMGB1. Scoring for each section was evaluated using a 0
to 4 scale with increments of 0.5. Index 0 corresponded to no
HMGB1 expression and 4 to the highest degree of HMGB1
protein expression. Separate analyses were performed for lin-
ing layers, vessels and cellular infiltrates in each of the sec-
tions. Nuclear, cytoplasmic and extracellular expression of
HMGB1 was also recorded from each tissue compartment.
Real-time RT-PCR
Due to a shortage of biopsy material, mRNA analysis was only
possible in six of the nine included patients. For first-strand
synthesis of each biopsy, 1 μg total RNA was mixed with 2 μl
20 TVN primer (4 μg/μl, Operon Biotechnology Inc. Huntsville,
AL USA). The primer sequences used were: for β-actin, for-
ward CCTTCGTGCCCCCCC and reverse GGAGAC-
CAAAAGCCTTCATACATC; and for HMGB1, forward
ATTGGTGATGTTGCGAAGAA and reverse GATCCACAG-
CAACTCCAGAA. The volume was adjusted to 15.5 μl using
RNase-free water, and the mixture was then incubated for 10
minutes at 70°C to denature the total RNA. The sample was
then incubated for two minutes on ice to allow the primers to
anneal and then spun briefly.
A 12.5 μl cDNA synthesis mixture, consisting of 6 μl 5× first-
strand buffer, 3 μl 0.1 M dithiothreitol (DTT), 2 μl Superscript
III (Invitrogen Corporation, Carlsbad, CA, USA), and 1.5 μl 10
mM deoxinucleoside triophosfate (dNTP) mix (Amersham Bio-
sciences, Piscataway, NJ, USA), was added to the sample.
The whole mixture was incubated at 46°C for first-strand syn-
thesis. After one hour the temperature was increased to 70°C
for 15 minutes to terminate the reaction. 2 U RNase H (Invitro-
gen Corporation, Carlsbad, CA, USA) was then added to
degrade the RNA. After RNase treatment the temperature was
increased to 70°C to inactivate RNases. All samples were
then diluted with RNase-free water to a final volume of 200 μl.
Real-time RT-PCR was performed using the iCycler system
from Bio-Rad Laboratories Inc. Hercules, CA, USA. Each reac-
tion was performed with a 3.0 μl template, 12.5 μl iQSYBR
Green Supermix (Bio-Rad Laboratories Inc. Hercules, CA,
USA), 300 nM primer and water to adjust the final volume to
25 μl. The PCR amplification steps were applied in the follow-
ing conditions: three minutes at 95°C, 40 cycles of 20 sec-
onds at 94°C, 30 seconds at 60°C and one minute at 72°C.
This was followed by melt curve analysis to ensure specific
amplification. The signal was calculated in all experiments
using 'PCR baseline subtracted relative flourescent unit
(RFU)'. All primers were designed using Primer3 and ampli-
cons were designed to span exon-exon junctions to minimise
contamination of genomic DNA [41]. Primer sequence infor-
mation is available in the supplemental material. Relative
expression between samples was calculated using the ΔΔCt
method and all samples were analysed in triplicate[42]. β-actin
was used as a reference housekeeping gene.
Statistical analysis
Wilcoxon's signed-rank test was used for the analysis of
matched pairs for protein data. as well as for the analysis of
mRNA data for the whole group. Spearman rank sum test was
utilised to statistically compare the degree of correlation
between the two persons evaluating HMGB1 protein expres-
sion by immunohistochemistry. p < 0.05 was considered to be
statistically significant.
Results
Clinical response and CD marker changes following 
infliximab treatment
Patients were assessed for disease activity at baseline and
after three months using individual DAS28 and ACR scores
(Table 1). These data have been previously published [38].Page 3 of 8
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0.01), the median tender joint count from 10 to 3 (p < 0.05),
the median swollen joint count from 14 to 2 (p < 0.01) and the
median serum C-reactive protein level decreased from 34 mg/
L to 19 mg/L (p = 0.08). Two patients fulfilled ACR70, one
patient fulfilled ACR50, three patients fulfilled ACR20 and
three patients were non-responders according to the ACR
criteria.
In repeated biopsies from each patient before and after inflixi-
mab treatment, expression of CD markers for T-cells (CD3),
macrophages (CD68) and activated macrophages (CD163)
were analysed. CD3 and CD163 were unaffected, whereas
the number of CD68-positive cells decreased as a conse-
quence of infliximab therapy (data not shown).
Synovial HMGB1 protein expression not influenced by 
infliximab therapy
Aberrant synovial HMGB1 staining was evident in all nine
patients before and during infliximab treatment and was most
prominent in the lining layer, in areas with cellular infiltrates and
in certain blood vessel walls. Both an increased (Figures 1a,b)
and decreased (Figures 1c,d) presence of HMGB1 protein in
the synovia during therapy could be detected, but there was
no correlation with the clinical course of individual patients. In
the group of six patients who responded to therapy, three had
a decreased, two had an increased and one had an
unchanged level of protein expression of HMGB1.
There was no significant difference in the group in the overall
HMGB1 protein distribution before or after infliximab therapy
(Figure 2). Neither were any consistent changes (nuclear,
cytoplasmic or extracellular) recorded for HMGB1 expression
when different biopsy compartments, including lining layer,
cell infiltrates and endothelium, were analysed separately.
HMGB1 mRNA expression not influenced by infliximab 
therapy
In the group of six patients studied by RT-PCR two individuals
had increased, two had decreased and two patients had
unchanged HMGB1 mRNA levels, with no correlation to clini-
cal outcomes. Taken together, the results indicated no
significant change of HMGB1 mRNA as a consequence of inf-
liximab therapy (Figure 3).
Table 1
Clinical assessment, response to infliximab treatment and HMGB1 expression.
Pat W Sex Age (years) Disease duration (years) CRP Medication DAS28 Clinical response HMGB1 protein HMGB1mRNA
MTX Pred DAS28 ACR ES CG
1 0 F 55 18 107 17.5 5 * 6.71 1.5 1
9 38 6.34 No 0 2 1.5
2 0 F 52 6 14 7.5 7.5 6.00 1.5 1.5
9 15 4.43 Mod 20 1 0.5 0
3 0 F 58 2 46 10 7.91 3 4
9 25 5.41 Mod 50 1 1.5 0
4 0 F 57 4 7 10 4.94 2 2
9 34 4.41 No 20 2 2 Up
5 0 M 56 7 44 15 5.95 2 2.5
9 7 2.90 G 70 3.5 3
6 0 F 69 1 69 15 5 7.39 2 3
9 7 1.79 G 70 1.5 2.5 Up
7 0 F 66 14 34 10 5.64 2 2
9 16 4.73 Mod 0 1 0.5 Down
8 0 F 66 10 18 12.5 4.83 3.5 4
9 19 4.23 Mod 0 0.5 2 Down
9 0 M 25 0.6 26 17.5 7.5 5.62 .5 3
9 25 3.91 Mod 20 3 4
* Patient 1 also received 150 mg/day cyclosporine before and during the study period.Pat = Patient, W = week, CRP = C-reactive protein, MTX 
= Methotrexate (mg/week), Pred = Prednisone (mg/day), DAS28 = disease activity score calculated on 28 joints, ACR = American College of 
Rheumatology, HMGB1 = High-mobility group box chromosomal protein 1, ES = Erik Sundberg, CG = Cecilia Grundtman, F = Female, M = 
Male, No = Non, Mod = Moderate, G = Good.Page 4 of 8
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To the authors' knowledge, this is the first clinical study exam-
ining the effect of TNF blockade on synovial HMGB1 expres-
sion. The expression of synovial HMGB1 protein and mRNA in
RA synovitis remained unaffected by TNF blockade for nine
weeks and there was no correlation with the clinical course of
arthritis. This was somewhat surprising as the original discov-
ery of extranuclear and extracellular HMGB1 translocation
was derived from studies of macrophages stimulated by TNF,
IL-1β or endotoxin. Blocking intra-articular TNF by infliximab
might therefore theoretically inhibit synovial HMGB1 release.
However, this could not be verified from the results of the
present study. There are several additional molecules such as
IL-1β, IFN-γ, IFN-β, Nitric oxide and multiple TLR ligands that
are potent promotors of HMGB1 translocation and extracellu-
lar release, and expression of all these mediators may possibly
remain unchanged during infliximab therapy [43-45]. Support-
ing the clinical data for the TNF-independent release of
HMGB1 are results obtained using a sensitive HMGB1 Elis-
pot assay, which demonstrated that TNF has a distinctly infe-
rior capacity to stimulate HMGB1 release from cultured
macrophages compared with other molecules such as endo-
toxin, IFN-γ [46] or IL-1β (authors' unpublished data).
A similar arthroscopic-guided tissue sampling method and
immunohistochemical analysis have previously been used to
study the therapeutic effects of systemic infliximab therapy on
the synovial expression of other important pro-inflammatory
molecules [38,47]. Infliximab treatment in another small cohort
of patients with RA saw the number of TNF-synthesising cells
readily reduced and the production of IL-1α and IL-1β incon-
sistently down-regulated[47]. IL-15 was not inhibited by anti-
TNF therapy in the same cohort of patients with RA as evalu-
ated in the present study [38]. Therefore, beneficial clinical
results after infliximab therapy may occur despite the fact that
active cytokines such as IL-1, IL-15 and HMGB1 prevail dur-
ing synovitis. Using a similar methodology contrasting results
regarding HMGB1 expression in RA synovitis based on ther-
apy with intra-articular corticosteroid injections was recently
demonstrated [48]. Local intra-articular corticosteroid treat-
ment clearly down-regulated the aberrant extranuclear expres-
sion of HMGB1. Likewise, TNF and IL-1β, but not IL-1α, were
strongly suppressed by intra-articular corticosteroid therapy.
In the present study HMGB1 was analysed in a semi-quantita-
tive way using conventional manual microscopy. Computer-
ised image analysis was not an option because this
technology does not enable discrimination between the con-
stitutive nuclear HMGB1 expression and the aberrant pres-
ence of cytoplasmic and extracellular HMGB1 causing
pathology.
The question regarding a functional relationship between TNF
and HMGB1 in rheumatoid synovitis cannot be fully clarified in
the present study due to the relatively limited number of
patients with RA. However, it is proposed that the results can
be interpreted in at least two different ways: HMGB1 and TNF
could either act independently of each other; or HMGB1 could
act upstream of TNF in the pro-inflammatory cascade. The lat-
ter explanation is favoured, since it has previously been
reported that HMGB1 is a potent inducer of TNF production
in cultured macrophages and dendritic cells [16,49,50]. In
addition, it has recently been demonstrated that HMGB1 up-
regulates TNF transcription by direct binding to the TNF pro-
motor in osteoclasts [51]. Furthermore, successful HMGB1-
targeted therapies in experimental sepsis, arthritis and brain
ischaemia strongly down-regulate in vivo synthesis of TNF
[29,52,53]. Another possibility to explain the lack of correla-
tion between the clinical course and HMGB1 expression fol-
lowing infliximab treatment could be that HMGB1 may be
more dependent on the IL-1 pathway than the TNF pathway in
the pathogenesis of arthritis. This theory is also supported by
the fact that intra-articular HMGB1 injections cause arthritis in
wild-type mice but not in IL-1 type I-receptor deficient mice [5].
Considering that exaggerated and dysregulated HMGB1
release may lead to aggravated inflammation and tissue
destruction in chronic arthritis, the results of the present study
suggest that HMGB1 may serve as a possible TNF-independ-
ent target molecule for biological therapy. Future work is
required to elucidate the potential of this strategy.
Figure 1
HMGB1 synovial protein expression before and during infliximab ther-apy as detected by immunohistochemistry
apy as detected by immunohistochemistry. Nuclear, cytoplasmic and 
extracellular HMGB1 protein expression is evident in the RA synovia in 
the lining layer as well as in cellular infiltrates and endothelium. (a) 
Moderate aberrant synovial HMGB1 expression before the start of inf-
liximab therapy from patient number 5. (b) The second biopsy in patient 
number 5 taken during infliximab treatment showing increased extranu-
clear HMGB1 staining. (c) A marked endothelial expression of HMGB1 
is evident before infliximab therapy in synovitis obtained from patient 
number 7. (d) Infliximab therapy for nine weeks resulted in reduced 
endothelial HMGB1 expression in patient number 7. Original magnifica-
tion ×250 for (a) and (b), ×100 for (c) and (d).Page 5 of 8
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A number of published observations have demonstrated that
the pro-inflammatory mediator HMGB1 has a functional
impact on the pathogenesis of arthritis. The results presented
here reveal an unaffected expression of HMGB1 at protein
and mRNA levels in synovia obtained from patients with RA
from repeated biopsies before and during well-established
TNF blockade with infliximab. These results are interpreted as
an indication of TNF-independent HMGB1 expression with
subsequent residual HMGB1 biological activity in RA synovitis
in spite of infliximab therapy. It is concluded that these findings
support attempts to generate novel HMGB1-targeted thera-
pies in chronic arthritis.
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